Kwan Ho Tang

8PUBLICATIONS
62CO-AUTHORS
Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

|Mar 06, 2026
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.

Zofia Piotrowska, Myung-Ju Ahn, Pei Jye Voon

|Mar 06, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.

Helena A Yu, Kwan Ho Tang, Aleksandra A Markovets

|Jun 04, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.

Jonathan W Riess, Adrianus J de Langen, Santiago Ponce

|Jul 10, 2024
Cellular adaptation to cancer therapy along a resistance continuum.

Gustavo S França, Maayan Baron, Benjamin R King

|Dec 16, 2021
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.

Chewei Anderson Chang, Jayu Jen, Shaowen Jiang

Pageof 2

Frequent Collaborators

4 joint publications

Byoung Chul Cho

4 joint publications

Zofia Piotrowska

3 joint publications

Helena A Yu

3 joint publications

Sarah B Goldberg